Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF

被引:0
|
作者
M Offidani
L Corvatta
A Olivieri
S Rupoli
J Frayfer
A Mele
E Manso
M Montanari
R Centurioni
P Leoni
机构
[1] Ancona University School of Medicine,Department of Hematology
[2] Torrette Hospital,Department of Microbiology
来源
关键词
infections; peripheral blood progenitor cell transplantation; mucositis; neutropenia; antimicrobial prophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
Infectious complications after autologous peripheral blood progenitor cell transplantation (PBPCT) have been reported in a few studies including small patient numbers. The present study was performed to assess the incidence, types, outcome and factors affecting early and late infections in 150 patients aged 18 to 68 years (median 46.5) who underwent high-dose therapy, with G-CSF. Patients were kept in reverse isolation rooms and received antimicrobial chemoprophylaxis with oral quinolone and fluconazole. One hundred and fifteen patients (76.7%) developed fever (median 3 days, range 1–29); 20 patients (55.5%) had Gram-positive and 13 (36.2%) Gram-negative bacterial infections. There were no fungal infections or infection-related deaths. Mucositis grade II–IV (P = 0.0001; odds ratio 3.4) and >5 days on ANC<100/μl (P = 0.0001; odds ratio 2.3) correlated with development of infection. Only days with ANC <100/μl affected infection outcome (P = 0.0024) whereas the antibiotic regimen did not. After day +30 there were four cases of bacterial pneumonitis (2.7%), one case of fatal CMV pneumonia (0.8%) and 20 of localized VZV infection (13.3%). Reduction of neutropenia duration with PBPCT and G-CSF is not enough to prevent early infectious complications since only a few days of severe neutropenia and mucositis are related to development of early infections. However, no infection-related deaths were seen. Although Gram-positive organisms were the major cause of bacteremia, a glycopeptide in the empirical antibiotic regimen did not affect infection outcome. In PBPCT recipients, early and late opportunistic infections were notably absent, which was at variance with what was seen with bone marrow recipients. Efforts should be made to prevent mucositis and neutropenia and identify new strategies of antibacterial prophylaxis.
引用
收藏
页码:1079 / 1087
页数:8
相关论文
共 50 条
  • [21] Efficacy of increased dose G-CSF in poorly mobilizing autologous peripheral blood progenitor cell (PBPC) patients
    Aysola, A
    Donnenberg, AD
    Buchbarker, D
    Hammert, L
    Kiss, JE
    TRANSFUSION, 1999, 39 (10) : 102S - 102S
  • [22] Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α
    Michallet, M
    Thiébaut, A
    Philip, I
    Charrin, C
    Vigouroux, C
    Thomas, X
    Bilger, K
    Belhabri, A
    Guyotat, D
    Corront, B
    Salles, B
    Dumontet, C
    Peaud, PY
    Vilque, JP
    Devidas, A
    Fière, D
    LEUKEMIA, 2000, 14 (12) : 2064 - 2069
  • [23] Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α
    M Michallet
    A Thiébaut
    I Philip
    C Charrin
    C Vigouroux
    X Thomas
    K Bilger
    A Belhabri
    D Guyotat
    B Corront
    B Salles
    C Dumontet
    PY Péaud
    JP Vilque
    A Devidas
    D Fière
    Leukemia, 2000, 14 : 2064 - 2069
  • [24] A randomized, multicenter study of G-CSF starting on day+1 vs day+5 after autologous peripheral blood progenitor cell transplantation
    de Azevedo, AM
    Nucci, M
    Maiolino, A
    Vigorito, AC
    Simoes, BP
    Aranha, FJP
    Tabak, DG
    Voltarelli, J
    de Souza, C
    BONE MARROW TRANSPLANTATION, 2002, 29 (09) : 745 - 751
  • [25] Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation
    C Colby
    SL McAfee
    DM Finkelstein
    TR Spitzer
    Bone Marrow Transplantation, 1998, 21 : 1005 - 1010
  • [26] Pegylated G-CSF after autologous hematopoietic stem cell transplantation
    Annaloro, C.
    Usardi, P.
    Della Volpe, A.
    Onida, F.
    Basilico, C.
    Deliliers, G. Lambertenghi
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 74 - 74
  • [27] Comparison of G-CSF and GM-CSF usage after autologous peripheral blood stem cell transplantation (Pbsct): a prospective study results
    Mirzaoglu, H
    Arpaci, F
    Ozturk, B
    Komurcu, S
    Ozet, A
    Turan, M
    Beyzadeoglu, M
    Sengul, A
    Yalcin, A
    BONE MARROW TRANSPLANTATION, 2001, 27 : S164 - S165
  • [28] Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.
    Piccirillo, N
    Sica, S
    Laurenti, L
    Chiusolo, P
    La Barbera, EO
    Sora, F
    Leone, G
    BLOOD, 1998, 92 (10) : 371B - 371B
  • [29] Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients
    Wylezol, Iwona
    Snarski, Emilian
    Markiewicz, Miroslaw
    Kyrcz-Krzemien, Slawomira
    Jedrzejczak, Wieslaw-Wiktor
    Walewski, Jan
    ANNALS OF TRANSPLANTATION, 2013, 18 : 336 - 341
  • [30] Administration of G-CSF after autologous peripheral stem cell transplantation is clinical and cost-effective
    Fruchart, C
    Journet, V
    Damourette, S
    Rivière, A
    German, O
    Musafiri, D
    Peny, AM
    BONE MARROW TRANSPLANTATION, 2004, 33 : S120 - S120